A Randomized, Open-label, Single-dose, Two-cycle, Two-sequence, Cross-controlled Study Evaluating the Pharmacokinetic Effects of a High-fat Diet on Oral Administration of SHR2554 Tablets in Healthy Adult Subjects in China
Latest Information Update: 22 Dec 2022
At a glance
- Drugs SHR-2554 (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 16 Dec 2022 Status changed from active, no longer recruiting to completed.
- 23 Nov 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 28 Oct 2022 New trial record